Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Bates

Showing results (401-410 of 430) with videos related to

Pageof 43
Sort By:
Plos One|September 14, 2012
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivoMaria Beconi, Omar Aziz, Kim Matthews, et al.
Neurobiology of Disease|October 9, 2007
Increased metabolism in the R6/2 mouse model of Huntington's diseaseJorien M M van der Burg, Karl Bacos, Nigel I Wood, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2005
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivoXiaoqian Zhang, Donna L Smith, Anatoli B Meriin, et al.
Disease Models & Mechanisms|May 26, 2026
Molecular features of a Huntington's disease knock-in minipigAnastasiia Kolesnikova, Kirupa Sathasivam, Solaleh Khoramian Tusi, et al.
Plos One|March 27, 2019
Meso scale discovery-based assays for the detection of aggregated huntingtinWolfgang Reindl, Barbara Baldo, Jana Schulz, et al.
Somatic Cell and Molecular Genetics|January 1, 1994
Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeatChristine M Ambrose, Mabel P Duyao, Glenn Barnes, et al.
Brain : a Journal of Neurology|January 25, 2014
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulationUlrike Träger, Ralph Andre, Nayana Lahiri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Breast Cancer Research : BCR|April 19, 2015
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survivalDenise A Yardley, Peter A Kaufman, Weidong Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2013
Targeting H3K4 trimethylation in Huntington diseaseMalini Vashishtha, Christopher W Ng, Ferah Yildirim, et al.
Pageof 43

Showing results (401-410 of 430) with videos related to

Sort By:
Pageof 43
Plos One|September 14, 2012
Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivoMaria Beconi, Omar Aziz, Kim Matthews, et al.
Neurobiology of Disease|October 9, 2007
Increased metabolism in the R6/2 mouse model of Huntington's diseaseJorien M M van der Burg, Karl Bacos, Nigel I Wood, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2005
A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivoXiaoqian Zhang, Donna L Smith, Anatoli B Meriin, et al.
Disease Models & Mechanisms|May 26, 2026
Molecular features of a Huntington's disease knock-in minipigAnastasiia Kolesnikova, Kirupa Sathasivam, Solaleh Khoramian Tusi, et al.
Plos One|March 27, 2019
Meso scale discovery-based assays for the detection of aggregated huntingtinWolfgang Reindl, Barbara Baldo, Jana Schulz, et al.
Somatic Cell and Molecular Genetics|January 1, 1994
Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeatChristine M Ambrose, Mabel P Duyao, Glenn Barnes, et al.
Brain : a Journal of Neurology|January 25, 2014
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulationUlrike Träger, Ralph Andre, Nayana Lahiri, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 10, 2010
SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesisRuth Luthi-Carter, David M Taylor, Judit Pallos, et al.
Breast Cancer Research : BCR|April 19, 2015
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survivalDenise A Yardley, Peter A Kaufman, Weidong Huang, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 23, 2013
Targeting H3K4 trimethylation in Huntington diseaseMalini Vashishtha, Christopher W Ng, Ferah Yildirim, et al.
Pageof 43